Entasis Therapeutics
Waltham
About Entasis Therapeutics
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $199.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (May 2021)
- Ticker: nasdaq:ETTX
- Website: entasistx.com
- Phone: (781)810-0120
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/entasis-therapeutics-499 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.